New considerations in the design of clinical trials of acute kidney injury
Acute kidney injury is a common and frequently fatal disease without an effective early intervention. The translation of promising experimental treatments to effective clinical trials has been hampered by the lack of a means to detect acute kidney injury early. Novel biomarkers of kidney injury...
Saved in:
| Main Authors: | , , , |
|---|---|
| 格式: | Article |
| 语言: | English |
| 出版: |
Future Science
2011
|
| 主题: | |
| 在线阅读: | http://irep.iium.edu.my/10620/ http://irep.iium.edu.my/10620/ http://irep.iium.edu.my/10620/1/Clinical_Investigation_2011_Pickering.pdf |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
| 总结: | Acute kidney injury is a common and frequently fatal disease without an
effective early intervention. The translation of promising experimental
treatments to effective clinical trials has been hampered by the lack of a
means to detect acute kidney injury early. Novel biomarkers of kidney injury
have made early intervention possible and the first early intervention trial
has been run. Emerging issues are the timing of biomarker measurement,
the relationship of biomarker concentration with baseline renal function,
and determining a primary outcome that best reflects renal function. A new
generation of early intervention trials with increased prospects of finding
effective therapies are now possible utilizing currently available novel
biomarkers. Proposed new outcome measures will decrease the likelihood of
negative trials as a result of poor design. |
|---|